BUDIGALIMAB
UNII 6VDO4TY3OO

Substance Identification & Data

This profile provides standardized clinical and technical data for Budigalimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 6VDO4TY3OO.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2098225-93-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

6VDO4TY3OO

CAS Registry Number

2098225-93-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BUDIGALIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C137682

National Cancer Institute reference terminology for clinical and research data.

INN ID

10908

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-94

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Budigalimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

BUDIGALIMAB

Common Names & Synonyms

ANTI-PD1 MONOCLONAL ANTIBODY ABBV-181

BUDIGALIMAB [INN]

BUDIGALIMAB [USAN]

BUDIGALIMAB [WHO-DD]

IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1), (HUMAN-MUS MUSCULUS MONOCLONAL PR-1648817 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PR-1648817 .KAPPA.-CHAIN, DIMER

Systematic Nomenclature

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS PDCD1(PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN (1-448) (VH (HOMO SAPIENS IGHV1-46*01(76.5%)-(IGHD)-IGHJ6*03 (90.9%)) (8.8.11) (1-118)-HOMOSAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 R120>K(215) (119-216), HINGE (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 E12 (357), M14 (359) (342-446), CHS(447-448)) (119-448)), (221-219')-DISULFIDE WITH KAPPA LIGHT CHAIN(1'-219') (V-KAPPA (MUS MUSCULUS IGKV1-117*01(89.0%)/HOMO SAPIENS IGKV2-28*01 OR IGKV2-29*02 (85.0%)-HOMO SAPIENS IGKJ2*01 (100%)) (11.3.9) (1'-112')-HOMO SAPIENS IGKC*01, KM3 A45.1 (158), V101 (196) (113'-219'))DIMER (227-227'':230-230'')-BISDISULFIDE IMMUNOMODULATOR, ANTINEOPLASTIC

SYS